← Home / Faeth Therapeutics, Inc. (SNSE)
Stock Analysis
Faeth Therapeutics, Inc. (SNSE)
SNSE
SNSE · Market data
22.92 -3.13%
52W Range Position
57%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-07-10 00:04 UTC
WOI Investment Thesis
Constructive
Confirmation improves above 35.07. Holding above 21.01 keeps the current thesis intact.
⚖️
✓
Fundamentals
Insufficient / Insufficient
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
21.01
↗
Break Above
Confirmation improves above resistance.
35.07
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 21.01
What's Driving SNSE?
📈 Technical recovery is improving
Momentum is Neutral. Watch 35.07 for confirmation and 21.01 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
Below 21.01
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
57.3
◎
How to read this setup
From a roadmap perspective, the setup is boxed by support near 20.97 and resistance around 25.78. A cleaner push through resistance would improve continuation odds, while a loss of support would weaken the current thesis.
Price Chart
SNSE · WOI overlay chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-09
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$30.7M
Company size
EV
$-121.0M
Debt-adjusted value
P/E
-1.5
Not meaningful
P/B
-0.2
Not meaningful
EV/EBIT
5.4
Low multiple
P/FCF
-1.3
Not meaningful
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Insufficient
●
Profitability
Insufficient
≈
Cash Flow
Recovering
⚖
Balance Sheet
Strong
📈 Net Income
-170.24M
≈ Insufficient
🧮 EPS (Basic)
-131.45
≈ Insufficient
Faeth Therapeutics, Inc.
Related Opportunities